Browse studies

Find your next paid study

18 recruiting studies matching your filters

Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia an…

MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis

Estimated

~$10 – $7,500

John MascarenhasNCT07447817

Phase 2

A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with tra…

Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06517875

Phase 2

A Phase 2 Study Of Ruxolitinib In Low-Risk Essential Thrombocythemia And Polycythemia Vera With Significant Symptom Burden

This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycyth…

Essential ThrombocythemiaPolycythemia Vera

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT04644211

Phase 2

Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary…

Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)

Estimated

~$10 – $6,250

Icahn School of Medicine at Mount SinaiNCT05835466

Phase 3

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include pa…

Thrombocythemia, EssentialPrimary MyelofibrosisMyelofibrosis+3 more

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT06351631

Phase 2

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was i…

Polycythemia Vera (PV)Essential Thrombocythemia (ET)Myelofibrosis (MF)

Estimated

~$10 – $6,250

Icahn School of Medicine at Mount SinaiNCT06541249